
Dracen Pharmaceuticals: Innovating cancer treatment through novel glutamine antagonists.
Founded with a mission to innovate cancer treatment, Dracen Pharmaceuticals focuses on developing novel glutamine antagonists aimed at improving outcomes for cancer patients. The company leverages immuno-metabolism to create potential new treatments, specifically targeting advanced solid tumors and fibrolamellar carcinoma. Their market focus is on providing advanced therapeutic options for patients with limited treatment choices, thereby addressing significant unmet medical needs in oncology.
Dracen Pharmaceuticals has notable affiliations, including a clinical collaboration with Merck and support from the Fibrolamellar Cancer Foundation (FCF). Key achievements include the initiation of a first-in-human study of their lead compound, DRP-, and a phase I/II study in combination with Durvalumab for fibrolamellar carcinoma. These milestones underscore Dracen's impact on advancing cancer treatment and their commitment to bringing innovative therapies to market.

Novita Pharmaceuticals
novita-pharm.com

Onchilles Pharma

Cage Pharma
cagephar.ma

Lite Strategy
meipharma.com

NextCure
nextcure.com

Toragen
toragen.com

BioNumerik Pharmaceuticals

Duet BioTherapeutics

Rainier Therapeutics

Trio Pharmaceuticals

Palleon Pharmaceuticals
palleonpharma.com

ImmunoMet Therapeutics
immunomet.com

Panacea Pharmaceuticals

Accelerated Pharma

Blueprint Medicines
Companies similar to Dracen Pharmaceuticals include Novita Pharmaceuticals, Onchilles Pharma, Cage Pharma and Lite Strategy.
Dracen Pharmaceuticals was founded in 2016.
Dracen Pharmaceuticals' headquarters is located in Baltimore, MD, US.
Dracen Pharmaceuticals' most recent funding round was for $2.3M (USD) in August 2023.
As of Aug 10, 2023, Dracen Pharmaceuticals has raised a total of $50.9M (USD).
Dracen Pharmaceuticals has 375 employees as of Feb 4, 2024.